Reports Q4 revenue $84.000 vs $76,000 last year. “Based on our significant progress in 2024, we are now positioned to announce two key data readouts for repibresib gel and VYN202 in 2025,” said David Domzalski, President and Chief Executive Officer of VYNE. “We are off to a strong start in 2025. In January, we announced the completion of enrollment in the Phase 2b trial of our locally administered pan-BD BET inhibitor, repibresib, in nonsegmental vitiligo, and we expect to report topline results in mid-2025. We also recently initiated the Phase 1b trial of our oral BD2-selective BET inhibitor, VYN202, in subjects with moderate-to-severe plaque psoriasis, and we anticipate reporting topline results from this trial by the end of this year.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYNE:
- VYNE Therapeutics: Promising Pipeline and Strategic Focus Drive Buy Rating
- Positive Outlook on VYNE Therapeutics Driven by Promising VYN202 Developments and Selective BD2 Targeting
- VYNE Therapeutics Receives Buy Rating: Promising Clinical Advances in Plaque Psoriasis Treatment
- VYNE Therapeutics announces dosing of first patient in Phase 1b trial of VYN202
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue